Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

TPST


Top 10 Correlated ETFs

TPST


Top 10 Correlated Stocks

TPST


In the News

04:05 30 Sep 2022 TPST

Tempest to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 a.m. ET.

05:52 30 Sep 2022 TPST

3 Must Watch Penny Stocks For Your Small-Caps List

These must watch penny stocks are worth giving a look The post 3 Must Watch Penny Stocks For Your Small-Caps List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

12:09 30 Sep 2022 TPST

Why Tempest Therapeutics Shares Are Rising

Tempest Therapeutics Inc (NASDAQ: TPST) shares are trading higher by 29.24% at $3.05 after the company announced $15 million of private placement financing.  The $15 million private investment in public equity (PIPE) financing comes from the sale of 3,149,912 shares of Tempest Therapeutics.

08:00 30 Sep 2022 TPST

Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 10:40 a.m. ET.

04:30 30 Sep 2022 TPST

Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced two poster presentations at the 2022 American Association for Cancer Research (AACR) virtual annual meeting taking place April 8-13, 2022. The presentations contain new preclinical data for two of Tempest's small molecule programs, TPST-1495 (clinical-stage dual EP2/4 antagonist) and TREX1 (preclinical STING agonist).

09:11 30 Sep 2022 TPST

H.C. Wainwright Says Targeted Oncology Therapies "Gives An Edge" To Tempest Therapeutics

H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc (NASDAQ: TPST) with a Buy rating and $51 price target, seeing an upside potential of over 100%.  A strategic portfolio of targeted therapies in oncology "gives Tempest an edge," analyst Joseph Pantginis tells investors in a research note.

03:12 30 Sep 2022 TPST

What's Going On With Tempest Therapeutics Stock?

Shares of the South San Francisco-based micro-cap biopharma Tempest Therapeutics Inc. (NASDAQ: TPST) were soaring Monday for a second consecutive trading session on above-average volume. Tempest's Wild Ride: Tempest, which recently began trading on the Nasdaq through a reverse merger with Millendo Therapeutics, is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors.

11:00 30 Sep 2022 TPST

MTSL Stock: 16 Things to Know About Penny Stock Mer Telemanagement as Shares Skyrocket

Mer Telemanagement (MTSL) stock is heading higher on Monday despite a lack of news from the company and heavy trading of shares. The post MTSL Stock: 16 Things to Know About Penny Stock Mer Telemanagement as Shares Skyrocket appeared first on InvestorPlace.

10:10 30 Sep 2022 TPST

TPST Stock: 13 Things to Know About Tempest Therapeutics as Shares Skyrocket Post-Merger

Tempest Therapeutics (TPST) stock is rocketing higher on Monday and reaching new highs since its merger with Millendo Therapeutics. The post TPST Stock: 13 Things to Know About Tempest Therapeutics as Shares Skyrocket Post-Merger appeared first on InvestorPlace.

08:35 30 Sep 2022 TPST

TPST Stock Increases over 120% Pre-Market: Why It Happened

The stock price of Tempest Therapeutics, Inc. (Nasdaq: TPST) increased by over 120% pre-market. This is why it happened.

Financial details

Company Rating
Neutral
Market Cap
17.82M
Income
-30.51M
Revenue
0
Book val./share
3.02
Cash/share
4.46
Dividend
-
Dividend %
-
Employees
17
Optionable
No
Shortable
Yes
Earnings
08 Nov 2022
P/E
0.26
Forward P/E
-
PEG
0.08
P/S
-
P/B
0.57
P/C
0.39
P/FCF
1.7
Quick Ratio
2.3
Current Ratio
3.05
Debt / Equity
0.02
LT Debt / Equity
0.02
-
-
EPS (TTM)
-3.89
EPS next Y
-
EPS next Q
-
EPS this Y
47.34%
EPS next Y
-
EPS next 5Y
81.03%
EPS last 5Y
-57.87%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-33.05%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-33.33%
Inst Own
43.44%
Inst Trans
-11.98%
ROA
-43%
ROE
-85%
ROC
-0.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
10.42M
Shs Float
7.92M
-
-
-
-
Target Price
-
52W Range
1.66-15.5
52W High
-88.53%
52W Low
+72%
RSI
36
Rel Volume
0.01
Avg Volume
29.31K
Volume
208
Perf Week
-16.1%
Perf Month
-32.28%
Perf Quarter
-53.64%
Perf Half Y
-54.74%
-
-
-
-
Beta
-
-
-
Volatility
0.08%, 0.32%
Prev Close
0%
Price
1.72
Change
-2.82%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
2.930000
Net income per share
-506.44-270.15-442.79-5.49-4.27
Operating cash flow per share
-452.55-234.93-409.54-4.590
Free cash flow per share
-454.12-235.29-413.49-4.59-0.02
Cash per share
667.66771.66620.725.757.81
Book value per share
638.8704.9581.67-10.375.44
Tangible book value per share
638.8726.47594.825.085.44
Share holders equity per share
638.8704.9581.67-10.375.44
Interest debt per share
07.01-6.580.120.72
Market cap
24.69M15.48M12.77M196.07M24.55M
Enterprise value
8.98M-57.24M-49.33M158.67M-23.81M
P/E ratio
-0.48-0.57-0.29-5.39-0.87
Price to sales ratio
83.680000
POCF ratio
-0.54-0.65-0.31-6.440
PFCF ratio
-0.54-0.65-0.31-6.44-181.86
P/B Ratio
0.380.220.22-2.850.68
PTB ratio
0.380.220.22-2.850.68
EV to sales
30.450000
Enterprise value over EBITDA
-0.182.131.11-4.550.89
EV to operating cash flow
-0.22.421.2-5.210
EV to free cash flow
-0.22.421.19-5.21176.37
Earnings yield
-2.06-1.76-3.49-0.19-1.15
Free cash flow yield
-1.85-1.53-3.26-0.16-0.01
Debt to equity
00.01000
Debt to assets
0.120.130.20.220.51
Net debt to EBITDA
0.322.711.41.071.82
Current ratio
8.818.55.685.1215.47
Interest coverage
0-200.5543.740-21.05
Income quality
0.890.870.920.840
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
94.050000
Research and developement to revenue
62.160000
Intangibles to total assets
00000
Capex to operating cash flow
000.0100
Capex to revenue
-0.540000
Capex to depreciation
-0.1-1.13-0.38-0.02-0.36
Stock based compensation to revenue
23.370000
Graham number
2.7K2.07K2.41K35.7822.86
ROIC
-0.72-0.36-0.73-0.54-0.39
Return on tangible assets
-0.7-0.32-0.59-0.84-0.39
Graham Net
582.67680.24480.224.332.22
Working capital
60.98M73.61M58.61M32.91M64.5M
Tangible asset value
00000
Net current asset value
60.23M72.47M56.03M31.22M31.84M
Invested capital
00.010.01-0.010.1
Average receivables
01.32M795K314K0
Average payables
1.86M1.74M1.49M1.49M1.24M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
1.04K0000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.350000
Inventory turnover
00000
ROE
-0.79-0.38-0.760.53-0.78
Capex per share
-1.57-0.36-3.940-0.02

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
00000
Net income per share
-7.63-1.21-0.71-1.18-0.79
Operating cash flow per share
0-1.750-0.990
Free cash flow per share
-0.09-1.763.51-0.990.61
Cash per share
73.938.897.726.384.46
Book value per share
51.996.485.384.13.02
Tangible book value per share
51.996.485.384.13.02
Share holders equity per share
51.996.485.384.13.02
Interest debt per share
20.912.870.62.590.19
Market cap
10.35M97.2M35.47M24.23M24.88M
Enterprise value
-38.99M56.3M-12.89M-3.27M-24.99M
P/E ratio
-0.37-3-1.87-0.71-0.68
Price to sales ratio
00000
POCF ratio
0-8.250-3.410
PFCF ratio
-123.17-8.231.5-3.413.55
P/B Ratio
0.222.230.980.830.71
PTB ratio
0.222.230.980.830.71
EV to sales
00000
Enterprise value over EBITDA
5.75-7.443.240.412.89
EV to operating cash flow
0-4.7800.460
EV to free cash flow
464.21-4.77-0.550.46-3.56
Earnings yield
-0.68-0.08-0.13-0.35-0.37
Free cash flow yield
-0.01-0.120.67-0.290.28
Debt to equity
0.370.400.570.02
Debt to assets
0.360.350.510.560.51
Net debt to EBITDA
7.285.4112.163.425.76
Current ratio
7.210.0815.473.013.05
Interest coverage
-24.58-17.7-12.9-24.51-18.91
Income quality
01.4500.840
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.51-0.220.36-0.03-0.85
Stock based compensation to revenue
00000
Graham number
94.4513.279.2410.457.33
ROIC
-0.1-0.13-0.11-0.18-0.18
Return on tangible assets
-0.09-0.12-0.06-0.13-0.13
Graham Net
44.615.382.192.711.31
Working capital
60.7M56.35M64.5M41.9M45.88M
Tangible asset value
00000
Net current asset value
43.11M38.95M31.84M25.11M31.89M
Invested capital
0.40.430.10.620.05
Average receivables
7.67M0015M0
Average payables
3.69M1.53M837.5K684K1.07M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.15-0.19-0.13-0.29-0.26
Capex per share
-0.09000-0.01

Frequently Asked Questions

What is Tempest Therapeutics, Inc. stock symbol ?

Tempest Therapeutics, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol TPST

What is Tempest Therapeutics, Inc. stock quote today ?

Tempest Therapeutics, Inc. stock price is $1.72 today.

Is Tempest Therapeutics, Inc. stock public?

Yes, Tempest Therapeutics, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap